DXCM Stock Summary and Trading Ideas (Dexcom | NASDAQ:DXCM)

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.

Dexcom trades on the NASDAQ stock market under the symbol DXCM.

As of October 22, 2026, DXCM stock price declined to $78.80 with 2,140,386 million shares trading.

DXCM has a beta of 0.77, meaning it tends to be less sensitive to market movements. DXCM has a correlation of 0.06 to the broad based SPY ETF.

DXCM has a market cap of $29.74 billion. This is considered a Large Cap stock.

Last quarter Dexcom reported $1 billion in Revenue and $.70 earnings per share. This beat revenue expectation by $16 million and exceeded earnings estimates by $.09.

In the last 3 years, DXCM traded as high as $142.00 and as low as $54.11.

The top ETF exchange traded funds that DXCM belongs to (by Net Assets): VTI, VOO, VO, QQQ, VUG.

DXCM has underperformed the market in the last year with a price return of +13.0% while the SPY ETF gained +14.8%. However, in the short term, DXCM had mixed performance relative to the market. It has outperformed in the last 3 months, returning +5.4% vs +2.2% return in SPY. But in the last 2 weeks, DXCM shares have been beat by the market, returning -6.5% compared to an SPY return of -1.8%.

DXCM support price is $78.58 and resistance is $81.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DXCM shares will trade within this expected range on the day.